Contact Your Financial Adviser Money Making MC
8 May
2017
Natco
Pharma on Monday said it has launched a generic version of sofosbuvir 400
mg/velpatasvir 100 mg tablets in India, which is used for treatment of chronic
hepatitis C virus (HCV) infection. The Total
Investment & Insurance Solutions
The
pharmaceutical company said in a regulatory filing to the BSE that it will
market the sofosbuvir 400 mg/velpatasvir 100 mg fixed dose combination in India
under the brand name 'Velpanat'. The Total
Investment & Insurance Solutions
According
to the company, the product is the generic version of the fixed dose
combination sold by Gilead Sciences globally under the brand name 'Epclusa'.
"Epclusa
is the first all-oral, pan-genotypic, single tablet regimen for the treatment
of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection,"
the BSE filing said.
The
company said the generic drug is priced at Rs 18,500 for a bottle of 28 tablets
in India.
"Natco
has signed a non-exclusive licensing agreement with Gilead Sciences, Inc., to
manufacture and sell generic versions of its chronic hepatitis C medicines in
101 developing countries," the company added. The Total Investment & Insurance Solutions
No comments:
Post a Comment